Secretome as a Tool to Treat Neurological Conditions: Are We Ready?

Due to their characteristics, mesenchymal stem cells (MSCs) are considered a potential therapy for brain tissue injury or degeneration. Nevertheless, despite the promising results observed, there has been a growing interest in the use of cell-free therapies in regenerative medicine, such as the use...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-11, Vol.24 (22), p.16544
Main Authors: da Silva, Andreia Valente, Serrenho, Inês, Araújo, Beatriz, Carvalho, Alexandre Martins, Baltazar, Graça
Format: Article
Language:English
Subjects:
Cells
central nervous system
Chemokines
Communication
conditioned medium
Cytokines
Enzymes
Extracellular vesicles
Ligands
Lipids
Medical research
Medicine, Experimental
mesenchymal stem cells
Metabolism
MicroRNAs
Pathology
preconditioning
Proteins
secretome
Stem cells
Transplantation
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Due to their characteristics, mesenchymal stem cells (MSCs) are considered a potential therapy for brain tissue injury or degeneration. Nevertheless, despite the promising results observed, there has been a growing interest in the use of cell-free therapies in regenerative medicine, such as the use of stem cell secretome. This review provides an in-depth compilation of data regarding the secretome composition, protocols used for its preparation, as well as existing information on the impact of secretome administration on various brain conditions, pointing out gaps and highlighting relevant findings. Moreover, due to the ability of MSCs to respond differently depending on their microenvironment, preconditioning of MSCs has been used to modulate their composition and, consequently, their therapeutic potential. The different strategies used to modulate the MSC secretome were also reviewed. Although secretome administration was effective in improving functional impairments, regeneration, neuroprotection, and reducing inflammation in brain tissue, a high variability in secretome preparation and administration was identified, compromising the transposition of preclinical data to clinical studies. Indeed, there are no reports of the use of secretome in clinical trials. Despite the existing limitations and lack of clinical data, secretome administration is a potential tool for the treatment of various diseases that impact the CNS.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms242216544